Anti-NMNAT1 Antibody

Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 ; NMN/NaMN adenylyltransferase 1;2.7.7.1;2.7.7.18; Nicotinamide-nucleotide adenylyltransferase 1; NMN adenylyltransferase 1; Nicotinate-nucleotide adenylyltransferase 1; NaMN adenylyltransferase 1; NMNAT1; NMNAT;

Widely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Catalyzes the formation of NAD (+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747) . Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747) . Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747) . Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD (+) (PubMed:17402747) . For the pyrophosphorolytic activity, prefers NAD (+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747) . Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257) . Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257) . Fails to cleave phosphorylated dinucleotides NADP (+), NADPH and NaADP (+) (PubMed:17402747) . Protects against axonal degeneration following mechanical or toxic insults (By similarity) .